CVS Caremark to end Largo, Fla., mail service pharmacy operations
LARGO, Fla. CVS Caremark has confirmed that it will close its mail service pharmacy operations in Largo, effective March 31, 2009.
“We continually review all operational strategies in each market and the decision to close this facility was made after careful consideration and because of integration activities since the merger of CVS and Caremark,” the company stated in an official statement sent to Drug Store News.
The move will impact about 200 employees. CVS stated that it is working with the impacted employees to place them in other positions for which they are qualified within the company, including CVS retail stores. If another job opportunity is not available, that employee will be eligible to receive a transition package to cover financial and health benefits, outplacement support and counseling.
“Caremark maintains a solid business continuity strategy with operational resources across the country. Dedicated teams are in place to prevent any disruption in mail pharmacy service to our clients and plan participants,” the company stated.
FDA approves generic version of Depakote
ROCKVILLE, Md. The Food and Drug Administration has approved a generic version of Abbott’s Depakote, FDA records show.
The agency approved Dr. Reddy’s Labs divalproex sodium delayed-release capsules in the 125 mg strength. The capsules are used to treat epilepsy, bipolar disorder and migraine headaches.
The branded version of the drug had sales of $1.5 billion in 2007, according to Abbott financial records.
FDA approves Mylan’s generic epilepsy drug
PITTSBURGH The Food and Drug Administration has approved Mylan’s generic version of GlaxoSmithKline’s epilepsy drug Lamictal, Mylan announced Wednesday.
The drug, known generically as lamotrigine, is also used to treat bipolar disorder. Mylan will sell the drug in the 25 mg, 100 mg, 150 mg and 200 mg strengths. The FDA also approved Genpharm?s application for a chewable generic version of Lamictal.
The branded version of the drug had sales of about $91 million in the year ending Sept. 30, according to IMS Health.